Successful treatment with gemtuzumab ozogamicin monotherapy in a pediatric patient with resistant relapse of acute myeloid leukemia
There are few therapeutic options in relapsed or refractory acute myeloid leukemia patients. CD33 antigen is expressed on approximately 90% of myeloblasts, and gemtuzumab ozogamicin, as a monoclonal antibody directed against the CD33 surface antigen, may be a good target for these patients. H...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Hacettepe University Institute of Child Health
2009-02-01
|
| Series: | The Turkish Journal of Pediatrics |
| Online Access: | https://turkjpediatr.org/article/view/2260 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | There are few therapeutic options in relapsed or refractory acute myeloid leukemia patients. CD33 antigen is expressed on approximately 90% of myeloblasts, and gemtuzumab ozogamicin, as a monoclonal antibody directed against the CD33 surface antigen, may be a good target for these patients. Herein, we present a 15-year-old acute myeloid leukemia patient who was resistant at relapse and could achieve remission with gemtuzumab ozogamicin at a total dose of 9 mg/m2, divided into three doses and delivered to hematopoietic stem-cell transplantation; however, the patient relapsed in a short time without application of transplantation.
|
|---|---|
| ISSN: | 0041-4301 2791-6421 |